PPM1H’s ability to reverse pathological Rab phosphorylation positions it as another potential therapeutic target for PD, with activity enhancers offering a novel approach to modulate LRRK2 signaling and mitigate disease progression. Here, LRRK2 is linked to Parkinson disease.